UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology
Rhea-AI Summary
UAV Corp (OTC: UMAV) and Genetic Networks have signed a Memorandum of Understanding (MOU) on April 07, 2025, forming a strategic partnership to develop solutions for detecting and countering biohazards. The collaboration will integrate 'sniffer' technologies into UMAV's airships and drones for real-time detection of nuclear, chemical, and biological hazards.
The two-year partnership combines UMAV's aerial systems with Genetic Networks' GeneScape™ platform and drug development capabilities. Key initiatives include:
- Integration of detection systems into UAV platforms
- Development of aerial-delivered countermeasures against threats
- Potential exclusive distribution partnership
- Joint R&D combining genome analysis with UAV expertise
Initial testing will be conducted on UMAV's airship at its Wewahitchka facility. Both companies currently hold Department of Defense (DoD) contracts and will support each other's government initiatives. While the MOU is non-binding, specific projects and funding will be formalized through subsequent agreements.
Positive
- Strategic partnership enhances UMAV's product offering with biohazard detection capabilities
- Access to Genetic Networks' 4,000 generic formulations network
- Potential for new DoD contract opportunities through mutual support
- Expansion into biohazard countermeasures market
Negative
- MOU is non-binding with no guaranteed financial outcomes
- Specific project details and funding arrangements still pending
- Implementation timeline for testing not yet determined
News Market Reaction
On the day this news was published, UMAV gained 6.92%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Genetic Networks Signs MOU with UMAV
WEWAHITCHKA, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- UAV Corp (OTC: UMAV), a leader in unmanned aerial vehicle (UAV) technology, and Genetic Networks, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY) and a pioneer in genetic perturbation and drug discovery, are excited to announce the signing of a Memorandum of Understanding (MOU) on April 07, 2025. This strategic partnership aims to develop innovative solutions for detecting and countering biohazards, contaminants, and related threats, leveraging UAV Corp’s advanced aerial systems and Genetic Networks’ proprietary GeneScape™ platform to enhance public safety, health, and security globally.
The collaboration integrates state-of-the-art “sniffer” technologies into UAV Corp’s airships and drones, enabling real-time detection of nuclear, chemical, and biological hazards. Genetic Networks, under the umbrella of Fifty 1 Labs, Inc. (OTC: FITY), contributes its expertise in biohazard identification and drug development—including a patented compound with potential broad-spectrum efficacy against infections—to create countermeasures deployable via UAV Corp’s aerial platforms. Initial testing will occur on UAV Corp’s airship, currently under completion at its Wewahitchka facility, advancing aerial threat response capabilities.
Both companies are actively engaged in Department of Defense (DoD) contracts, positioning them to assist each other in meeting stringent government requirements. UAV Corp’s UAV expertise complements Genetic Networks’ advancements in genetic science, offering mutual support for DoD initiatives. On April 1, 2025, FITY announced a groundbreaking yeast experiment launched on SpaceX’s Fram2 mission, engineered by Dr. Corey Nislow to study resistance to microgravity and cosmic radiation—data that could inform this collaboration’s countermeasure development. Genetic Networks will facilitate introductions between their relationships and UMAV’s management team to potentially unlock new opportunities for contracts and collaborations in the defense and space sectors.
“This partnership merges cutting-edge aerial technology with genetic innovation to tackle critical global challenges,” said Michael Lawson, CEO of UAV Corp. “By equipping our UAV platforms with advanced detection systems and collaborating with Genetic Networks, we’re set to deliver rapid, impactful solutions to biohazard threats worldwide while strengthening our DoD efforts and exploring new avenues.”
Gennaro D’Urso, Founder, CEO, and Chairman of Genetic Networks, added, “Teaming up with UAV Corp amplifies the reach of our GeneScape™ platform and drug development efforts, as demonstrated by our recent SpaceX Fram2 mission experiment under Fifty 1 Labs, Inc. (OTC: FITY). Together, we’re poised to detect dangers and deploy life-saving countermeasures efficiently, utilizing our supplier network of approximately 4,000 generic formulations and supporting our shared DoD objectives.”
Key initiatives outlined in the MOU include:
- Detection Systems: Integrating sniffer technologies into UAV platforms to identify contaminants and biohazards.
- Countermeasures: Developing and distributing compounds to neutralize threats, including radiation and toxic substances, via aerial delivery.
- Distribution Partnership: Exploring Genetic Networks’ potential role as an exclusive agent for countermeasure distribution, supported by UAV Corp’s aerial capabilities.
- Joint R&D: Combining whole-genome analysis with UAV expertise to refine detection and response strategies.
The two-year collaboration, effective from the signing date, reflects both companies’ dedication to innovation and societal benefit. While the MOU serves as a non-binding framework, the parties plan to formalize specific projects and funding through subsequent agreements, with testing timelines to be detailed soon.
“We’re thrilled to launch this partnership,” Lawson and D’Urso said jointly. “It strengthens our capabilities, aligns our DoD efforts, and positions us to make a tangible impact on global health and security.”
About UAV Corp
UAV Corp (OTC: UMAV) is a global leader in unmanned aerial vehicle technology, delivering advanced solutions for security, surveillance, and aerial systems across government, defense, and commercial sectors. Headquartered in Wewahitchka, Florida, UAV Corp is committed to advancing aerial innovation.
Michael Lawson, CEO
Email: mlawson@uavcorp.net
Address: 115 County Road 381, Wewahitchka, FL 32465
Phone: 877-425-1066
Website: www.uavcorp.net
About Genetic Networks
Genetic Networks, a wholly owned subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), accelerates drug discovery and compound development through its proprietary GeneScape™ platform. The company is dedicated to advancing health solutions through genetic science and strategic partnerships
Investor Relations
877-814-4188
ir@fifty1labs.com
Website: https://geneticnetworks.com/
FAQ
What is the purpose of the UAV Corp (UMAV) and Genetic Networks partnership?
When does the UMAV-Genetic Networks collaboration agreement begin and how long will it last?
What technologies will be integrated into UMAV's aerial platforms?
Where will UMAV conduct initial testing for the biohazard detection systems?
How does the UMAV partnership relate to Department of Defense contracts?
